SCHEMBL18264173

SCHEMBL18264173

Nc1n[nH]c2c1c(Nc1ccc(Cl)cc1)nc1ccc(Cl)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GAA P10253 1/20 0.42
GFER P55789 1/20 0.42
TP53 P04637 1/20 0.41
CHEK1 O14757 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
RAB9A P51151 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
TRPA1 O75762 1/20 0.40
EGFR P00533 2/20 0.39
KDR P35968 1/20 0.39
LRRK2 Q5S007 1/20 0.39
NPY5R Q15761 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20423414 0.93 CHEK1 (0.43) MEN1KMT2ACHEK1ALDH1A1MAPT
SCHEMBL18264162 0.91 MEN1 (0.51) MEN1KMT2AGAAGFERKDM4E
SCHEMBL23906852 0.90 TRPA1 (0.43) MEN1KMT2AGAAGFERTP53
SCHEMBL18264159 0.88 MAPT (0.52) MEN1KMT2AGAAGFERTP53
SCHEMBL23906855 0.83 HSP90AB1 (0.43) MEN1KMT2ACHEK1ALDH1A1RAB9A
SCHEMBL18264172 0.80 PIM1 (0.43) MEN1KMT2AGAACHEK1ALDH1A1
SCHEMBL20423876 0.79 ADRB2 (0.43) MEN1KMT2ATP53KDM4EALDH1A1
SCHEMBL18264175 0.78 KDM1A (0.52) MEN1KMT2AGAATP53KDM4E
SCHEMBL18264402 0.78 EGFR (0.47) MEN1KMT2AGAAGFERTP53
SCHEMBL21670127 0.76 TRPA1 (0.42) MEN1KMT2AGAAGFERCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP claimed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US claimed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP claimed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO claimed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
US-20200113878-A1 PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2020-04-16 US disclosed
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE UGT1A3, UGT1A1, GUSB MEN1 4572/4885KMT2A 3526/4885GAA 96/4885
US-20200113878-A1 PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase UGT1A3, UGT1A1, GUSB MEN1 4572/4885KMT2A 3526/4885GAA 96/4885
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 MEN1 4607/4885KMT2A 3492/4885GAA 100/4885
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 MEN1 4607/4885KMT2A 3492/4885GAA 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.